Methylene blue in congenital methemoglobinemia: prophylactic or on demand?
To the Editor: We read with interest the article "Prophylactic methylene blue in a patient with congenital methemoglobinemia". 1 However, we feel the patient's condition did not warrant prophylactic administration of methylene blue. Surgery of this patient was cancelled previously because of severe hypoxia due to respiratory depression following induction of anesthesia without preoxygenation. But oxygenation had improved following ventilation with 100% oxygen, before giving methylene blue. 2 On this occasion however, the patient was preoxygenated following which, PaO 2 increased from 81.3 to 543 mmHg and SaO 2 from 96.2 to 99.7%. Preoxygenation itself provided an adequate margin of safety against hypoxia. Homozygotes and compound heterozygotes for cytochrome b5 reductase deficiency are cyanotic but asymptomatic even with methemoglobin levels up to 40%, and have less risk of acute deterioration after exposure to exogenous methemoglobin inducing agents. 3 Symptoms of oxygen deprivation appear only as methemoglobin levels rise above 30%. 4 Intravenous methylene blue is indicated only for emergency treatment of "toxic" methemoglobinemia 3 and is known to cause serious adverse effects.
In our opinion, anesthetic management of congenital methemoglobinemia should target oxygenation rather than methemoglobin levels, and pharmacological intervention to decrease methemoglobin levels should be attempted only when increased methemoglobin leads to impaired oxygenation. We feel that the authors should have proceeded without prophylactic administration of methylene blue and should have administered the drug only if increased methemoglobin levels lead to desaturation. Also, the authors should have ruled out G6PD deficiency.
Recently, we managed a case of congenital methemoglobinemia with coexisting Osler-Weber-Rendu syndrome. Despite associated pulmonary arteriovenous malformations, anesthesia was successfully managed without using methylene blue. 
